Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study.
Epstein - Barr virus
PTLD
allogeneic hematopoietic stem cell transplantation
outcome
solid organ transplantation
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
04
2023
accepted:
05
06
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Post-transplant lymphoproliferative disorders (PTLD) are heterogeneous lymphoid disorders ranging from indolent polyclonal proliferations to aggressive lymphomas that can arise after solid organ transplantation (SOT) and allogeneic hematopoietic transplantation (allo-HSCT). In this multi-center retrospective study, we compare patient characteristics, therapies, and outcomes of PTLD after allo-HSCT and SOT. Twenty-five patients (15 after allo-HSCT and 10 after SOT) were identified who developed PTLD between 2008 and 2022. Median age (57 years; range, 29-74 years) and baseline characteristics were comparable between the two groups (allo-HSCT vs SOT), but median onset of PTLD was markedly shorter after allo-HSCT (2 months vs. 99 months, P<0.001). Treatment regimens were heterogeneous, with reduction of immunosuppression in combination with rituximab being the most common first-line treatment strategy in both cohorts (allo-HSCT: 66%; SOT: 80%). The overall response rate was lower in the allo-HSCT (67%) as compared to the SOT group (100%). Consequently, the overall survival (OS) trended towards a worse outcome for the allo-HSCT group (1-year OS: 54% vs. 78%; P=0.58). We identified PTLD onset ≤150 days in the allo-HSCT (P=0.046) and ECOG >2 in the SOT group (P=0.03) as prognostic factors for lower OS. PTLD cases present heterogeneously and pose unique challenges after both types of allogeneic transplantation.
Sections du résumé
Background
UNASSIGNED
Post-transplant lymphoproliferative disorders (PTLD) are heterogeneous lymphoid disorders ranging from indolent polyclonal proliferations to aggressive lymphomas that can arise after solid organ transplantation (SOT) and allogeneic hematopoietic transplantation (allo-HSCT).
Methods
UNASSIGNED
In this multi-center retrospective study, we compare patient characteristics, therapies, and outcomes of PTLD after allo-HSCT and SOT. Twenty-five patients (15 after allo-HSCT and 10 after SOT) were identified who developed PTLD between 2008 and 2022.
Results
UNASSIGNED
Median age (57 years; range, 29-74 years) and baseline characteristics were comparable between the two groups (allo-HSCT vs SOT), but median onset of PTLD was markedly shorter after allo-HSCT (2 months vs. 99 months, P<0.001). Treatment regimens were heterogeneous, with reduction of immunosuppression in combination with rituximab being the most common first-line treatment strategy in both cohorts (allo-HSCT: 66%; SOT: 80%). The overall response rate was lower in the allo-HSCT (67%) as compared to the SOT group (100%). Consequently, the overall survival (OS) trended towards a worse outcome for the allo-HSCT group (1-year OS: 54% vs. 78%; P=0.58). We identified PTLD onset ≤150 days in the allo-HSCT (P=0.046) and ECOG >2 in the SOT group (P=0.03) as prognostic factors for lower OS.
Conclusion
UNASSIGNED
PTLD cases present heterogeneously and pose unique challenges after both types of allogeneic transplantation.
Identifiants
pubmed: 37427100
doi: 10.3389/fonc.2023.1208028
pmc: PMC10326719
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1208028Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Lückemeier, Radujkovic, Holtick, Kurch, Monecke, Platzbecker, Herling and Kayser.
Déclaration de conflit d'intérêts
UH received consulting fees or honoraria from Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Curr Hematol Malig Rep. 2013 Sep;8(3):173-83
pubmed: 23737188
Br J Radiol. 2015 Aug;88(1052):20140861
pubmed: 25989696
Eur J Haematol. 2019 Jun;102(6):465-471
pubmed: 30828868
Leukemia. 2022 Oct;36(10):2468-2478
pubmed: 35974101
Biol Blood Marrow Transplant. 2019 Jul;25(7):1441-1449
pubmed: 30794929
Clin Infect Dis. 2013 Sep;57(6):794-802
pubmed: 23771985
Transpl Infect Dis. 2019 Oct;21(5):e13145
pubmed: 31301099
Transpl Int. 2022 Dec 14;35:10707
pubmed: 36589262
Leuk Lymphoma. 2019 Jan;60(1):142-150
pubmed: 29966464
Transpl Int. 2014 Jul;27(7):721-32
pubmed: 24684689
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Cancer. 2018 Jun 1;124(11):2327-2336
pubmed: 29579330
Haematologica. 2016 Jul;101(7):803-11
pubmed: 27365460
Clin Transplant. 2018 Jan;32(1):
pubmed: 29114932
N Engl J Med. 2018 Feb 8;378(6):549-562
pubmed: 29414277
Ann Transplant. 2019 Apr 03;24:175-184
pubmed: 30940797
Am J Clin Pathol. 2012 Oct;138(4):568-78
pubmed: 23010712
Blood. 2009 May 14;113(20):4992-5001
pubmed: 19264919
Ann Hematol. 2019 Sep;98(9):2163-2177
pubmed: 31243569
Blood Adv. 2022 Sep 13;6(17):4949-4966
pubmed: 35819448
Leuk Lymphoma. 2021 Dec;62(14):3493-3500
pubmed: 34338127
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Expert Rev Clin Immunol. 2013 Feb;9(2):139-51
pubmed: 23390945
Clin Transplant. 2012 Jan-Feb;26(1):67-73
pubmed: 21269330
Am J Transplant. 2011 Feb;11(2):336-47
pubmed: 21219573
Front Oncol. 2022 Jan 17;11:790481
pubmed: 35111674
Transplantation. 2001 Apr 27;71(8):1076-88
pubmed: 11374406
Cancers (Basel). 2022 Apr 13;14(8):
pubmed: 35454860
Cancers (Basel). 2023 Feb 03;15(3):
pubmed: 36765933
J Clin Oncol. 2007 Feb 10;25(5):571-8
pubmed: 17242397
Lancet Oncol. 2012 Feb;13(2):196-206
pubmed: 22173060